{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fixed+dose", "query": { "intervention": "Fixed dose" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 2327, "total_pages": 233, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fixed+dose&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T22:16:12.793Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06295159", "title": "Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage III", "Melanoma Stage IV", "Advanced Melanoma", "Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2024-05-17", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-09-20T22:16:12.793Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06295159" }, { "nct_id": "NCT02245672", "title": "MGR001 / Advair Diskus Local Equivalence Study in Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)", "type": "DRUG" }, { "name": "Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Pharma UK Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1128, "start_date": "2014-10", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2022-02-24", "last_synced_at": "2026-09-20T22:16:12.793Z", "location_count": 101, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 84 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02245672" }, { "nct_id": "NCT07749586", "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "ARV-6723", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "SOC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arvinas Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 499, "start_date": "2026-07-29", "completion_date": "2032-03-31", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-20T22:16:12.793Z", "location_count": 3, "location_summary": "Huntersville, North Carolina • San Antonio, Texas • Fairfax, Virginia", "locations": [ { "city": "Huntersville", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07749586" }, { "nct_id": "NCT03546686", "title": "Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Core Biopsy/Cryoablation", "type": "PROCEDURE" }, { "name": "Breast Surgery", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 51, "start_date": "2019-11-12", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-20T22:16:12.793Z", "location_count": 4, "location_summary": "Los Angeles, California • Columbus, Ohio • Portland, Oregon + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03546686" }, { "nct_id": "NCT05444257", "title": "A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-121/TEZ/D-IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 822, "start_date": "2022-11-08", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-20T22:16:12.793Z", "location_count": 72, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05444257" }, { "nct_id": "NCT05286762", "title": "Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ADHD", "Attention Deficit Hyperactivity Disorder", "ADHD - Combined Type", "Attention Deficit Hyperactivity Disorder Combined", "Attention-deficit Hyperactivity", "Attention Deficit Hyper Activity" ], "interventions": [ { "name": "CTx-1301-Dexmethylphenidate 12.5 mg (titration only)", "type": "DRUG" }, { "name": "CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)", "type": "DRUG" }, { "name": "CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)", "type": "DRUG" }, { "name": "CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cingulate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 103, "start_date": "2023-08-01", "completion_date": "2024-02-29", "has_results": true, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-09-20T22:16:12.793Z", "location_count": 24, "location_summary": "Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Maitland", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Springfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05286762" }, { "nct_id": "NCT03227861", "title": "A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1" ], "interventions": [ { "name": "DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2017-07-31", "completion_date": "2019-09-04", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-09-20T22:16:12.793Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03227861" }, { "nct_id": "NCT04978454", "title": "Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Influenza RG-A/Texas/71/2017 (H3N2) Challenge", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 60, "start_date": "2021-08-19", "completion_date": "2022-09-22", "has_results": true, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-09-20T22:16:12.793Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Durham, North Carolina", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04978454" }, { "nct_id": "NCT02796677", "title": "AMPLIFY - D6571C00001 Duaklir USA Phase III Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)", "type": "DRUG" }, { "name": "Aclidinium bromide 400 μg (AB 400 μg)", "type": "DRUG" }, { "name": "Formoterol fumarate 12 μg (FF 12 μg)", "type": "DRUG" }, { "name": "Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg", "type": "OTHER" }, { "name": "Tiotropium 18 μg (TIO 18 μg)", "type": "DRUG" }, { "name": "Placebo to TIO 18 μg", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "40 Years to 130 Years" }, "enrollment_count": 1595, "start_date": "2016-07-05", "completion_date": "2017-06-08", "has_results": true, "last_update_posted_date": "2018-11-09", "last_synced_at": "2026-09-20T22:16:12.793Z", "location_count": 85, "location_summary": "Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more", "locations": [ { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02796677" }, { "nct_id": "NCT01102088", "title": "Simultaneous Integrated Boost (SIB) in Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2010-04", "completion_date": "2019-06-08", "has_results": false, "last_update_posted_date": "2020-05-22", "last_synced_at": "2026-09-20T22:16:12.793Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01102088" } ] }